Endo announced the launch of its reformulated, crush-resistant Opana ER (oxymorphone HCl extended-release) tablets in two new strengths, 7.5mg and 15mg.
Opana ER is a Class II opioid narcotic indicated for moderate to severe pain when the use of a continuous, around-the-clock opioid is required for an extended period of time; it is not for an “as-needed” use.
Opana ER is now available in 5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, and 40mg dosage strength tablets, all of which have been reformulated to be crush-resistant. According to surveillance data, the reformulated design correlated to reduced abuse rates when compared to the non-crush-resistant version that was discontinued in May.
For more information call (800) 462-ENDO or visit www.opana.com.